Traphaco JSCSTC:TRA -0.13%83 ROE % is 16.48% as of Mar. 2026, which is 14% below its 10-year median of 19.19. GuruFocus rates STC:TRA with a GF Score™ of 83/100 and a GF Value™ of ₫92,290.93 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 936 Drug Manufacturers companies, Traphaco JSC ranks better than 84.62% on this metric.
ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Traphaco JSC's annualized net income for the quarter that ended in Mar. 2026 was ₫246,452 Mil. Traphaco JSC's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was ₫1,495,587 Mil. Therefore, Traphaco JSC's annualized ROE % for the quarter that ended in Mar. 2026 was 16.48%.
The historical rank and industry rank for Traphaco JSC's ROE % or its related term are showing as below:
STC:TRA'
s ROE % Range Over the Past 10 Years
Min: 14.95 Med: 19.19 Max: 24.6
Current: 18.46
During the past 13 years, Traphaco JSC's highest ROE % was 24.60%. The lowest was 14.95%. And the median was 19.19%.
STC:TRA's ROE % is ranked better than 84.62% of 936
companies
in the Drug Manufacturers industry
Industry Median: 5.865
vs STC:TRA: 18.46
Traphaco JSC (STC:TRA) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Traphaco JSC ROE % Related Terms
Traphaco JSC ROE % Historical Data
* Premium members only.
The historical data trend for Traphaco JSC's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Traphaco JSC's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Traphaco JSC ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Traphaco JSC's ROE % distribution charts can be found below:
* The bar in red indicates where Traphaco JSC's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
ROE % is displayed in the 30-year financial page.
Traphaco JSC (STC:TRA) has a ROE % of 16.48% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Traphaco JSC and its competitors. This is 14% below median its historical median of 19.19. Over the past decade, Traphaco JSC's ROE % has ranged from 14.95 to 24.60. According to the industry distribution chart, Traphaco JSC ranks #144 out of 936 companies in the Drug Manufacturers industry, placing it in the top 15.4%.
Is Traphaco JSC's ROE % too high?
Traphaco JSC's current ROE % of 16.48% is 14% below median its 10-year median of 19.19. Over the past 10 years, this metric has ranged from a low of 14.95 to a high of 24.60. The Drug Manufacturers industry median ROE % is 5.87. Traphaco JSC's value of 16.48% is 181% above this industry median. Based on the distribution chart, Traphaco JSC ranks #144 out of 936 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Traphaco JSC has a GF Score™ of 83/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Traphaco JSC's ROE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Traphaco JSC ranks #144 out of 936 companies for ROE %. This places Traphaco JSC in the top 15% of its industry — outperforming the majority of peers. The industry median ROE % is 5.87. Traphaco JSC's value of 16.48% is 181% above this benchmark. Historically, Traphaco JSC's own ROE % has ranged from 14.95 to 24.60 over the past decade. While the company's 10-year median is 19.19 vs. the industry median of 5.87, Traphaco JSC has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Traphaco JSC's current ROE % of 16.48% is 181% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Traphaco JSC and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Traphaco JSC's current ROE % is 16.48%, which is 14% below median its own 10-year median of 19.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Traphaco JSC stock overvalued right now?
Based on GuruFocus' analysis, Traphaco JSC (STC:TRA) is currently considered Modestly Undervalued. The stock's GF Value™ is ₫92,290.93, compared to a current price of ₫77,900.00 — trading 15.6% below its estimated fair value. The current ROE % is 16.48%, which is 14% below median its 10-year median of 19.19 and 181% above the Drug Manufacturers industry median of 5.87. Traphaco JSC's overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Traphaco JSC (STC:TRA), the current ROE % is 16.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Traphaco JSC (STC:TRA) Overvalued in 2026?
Based on GuruFocus' analysis, Traphaco JSC stock appears to be undervalued.
The current stock price of ₫77,900.00 is trading 15.6% below its estimated GF Value™ of ₫92,290.93.
GuruFocus considers Traphaco JSC to be Modestly Undervalued.
Key valuation signals for STC:TRA:
ROE %: 16.48% (14% below median its 10-year median of 19.19)
GF Value™: ₫92,290.93 vs. price of ₫77,900.00 (15.6% below fair value)
Industry Position: 181% above the Drug Manufacturers median (#144 of 936)
No single metric tells the full story. See the STC:TRA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Traphaco JSC is engaged in the production and trading of pharmaceuticals, chemicals, and medical supplies and equipment. The company's products are used for nourishing the body, the Skeletal system, for hair, for eyes, the Nervous system, the Respiratory system, and Other groups.
83GF Score
Get the complete analysis for STC:TRA
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STC:TRA has been successfully added to your 
